Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities

(2022) Sarah J Tabrizi et al.   LANCET NEUROLOGY

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

(2022) Timothy M. Miller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tau immunotherapies: Lessons learned, current status and future considerations

(2020) L.A. Sandusky-Beltran et al.   NEUROPHARMACOLOGY

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

(2020) Timothy Miller et al.   NEW ENGLAND JOURNAL OF MEDICINE

BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain

(2020) Cyrille Sur et al.   BRAIN

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

(2020) Fangda Leng et al.   Nature Reviews Neurology

Targeting Huntingtin Expression in Patients with Huntington’s Disease

(2019) Sarah J. Tabrizi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease

(2019) Bernard J. Hanseeuw et al.   JAMA Neurology

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Tau Kinetics in Neurons and the Human Central Nervous System

(2018) Chihiro Sato et al.   NEURON

Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain

(2018) Sarah L. DeVos et al.   Frontiers in Neuroscience

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

(2018) Leslie M. Shaw et al.   Alzheimers & Dementia

Alzheimer's disease

(2017) C. A. Lane et al.   EUROPEAN JOURNAL OF NEUROLOGY

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

(2017) Stephane Nave et al.   JOURNAL OF ALZHEIMERS DISEASE

A Comparison of Accelerated and Non-accelerated MRI Scans for Brain Volume and Boundary Shift Integral Measures of Volume Change: Evidence from the ADNI Dataset

(2017) Emily N. Manning et al.   NEUROINFORMATICS

Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases

(2017) Kathleen M. Schoch et al.   NEURON

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

(2017) Sarah L. DeVos et al.   Science Translational Medicine

Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease

(2017) Chenjie Xia et al.   JAMA Neurology

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

(2016) Eric R. Siemers et al.   Alzheimers & Dementia

Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease

(2016) Florence Pasquier et al.   JOURNAL OF ALZHEIMERS DISEASE

Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model

(2016) Kathleen M. Schoch et al.   NEURON

Analysis of in vivo turnover of tau in a mouse model of tauopathy

(2015) Kaoru Yamada et al.   Molecular Neurodegeneration

Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients

(2015) Nicola De Stefano et al.   Multiple Sclerosis Journal

Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain

(2015) Shuko Takeda et al.   Nature Communications

Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody

(2015) Wenjie Luo et al.   Scientific Reports

Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation

(2015) Sara Calafate et al.   Cell Reports

Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients

(2015) Nicola De Stefano et al.   Multiple Sclerosis Journal

Seizure resistance without parkinsonism in aged mice after tau reduction

(2014) Zhiyong Li et al.   NEUROBIOLOGY OF AGING

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies

(2014) Reeteka Sud et al.   Molecular Therapy-Nucleic Acids

Antisense Reduction of Tau in Adult Mice Protects against Seizures

(2013) S. L. DeVos et al.   JOURNAL OF NEUROSCIENCE

Age-appropriate cognition and subtle dopamine-independent motor deficits in aged Tau knockout mice

(2013) Meaghan Morris et al.   NEUROBIOLOGY OF AGING

Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration

(2013) K. K. Leung et al.   NEUROLOGY

Lack of Tau Proteins Rescues Neuronal Cell Death and Decreases Amyloidogenic Processing of APP in APP/PS1 Mice

(2012) Karelle Leroy et al.   AMERICAN JOURNAL OF PATHOLOGY

Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in Neurons

(2012) Jessica W. Wu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

(2011) Heiko Braak et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Tau Protein Is Required for Amyloid  -Induced Impairment of Hippocampal Long-Term Potentiation

(2011) O. A. Shipton et al.   JOURNAL OF NEUROSCIENCE

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

(2011) S. Salloway et al.   NEUROLOGY

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

(2010) C. Frank Bennett et al.   Annual Review of Pharmacology and Toxicology

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

(2010) Lars M. Ittner et al.   CELL

Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport: Fig. 1

(2010) Keith A. Vossel et al.   SCIENCE

Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database

(2008) S. M. Nestor et al.   BRAIN

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

(2008) R. Zivadinov et al.   NEUROLOGY

Differential Regulation of Dynein and Kinesin Motor Proteins by Tau

(2008) R. Dixit et al.   SCIENCE